This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
PCVs, in countries where implemented, have been successful in reducing the number of cases of vaccine-type diseases.1
Prevenar 13® represents a public health success for society worldwide.1
At Pfizer, we are proud of this achievement and recognise that it could not have happened without a highly experienced team, some of whom have been here for over 20 years,2 working closely with healthcare professionals around the world.
Pfizer strives for vaccine supply reliability3 by using a highly integrated and adaptable global manufacturing and distribution network.2-4
Thousands of dedicated manufacturing colleagues each play their role in bringing every single dose of Prevenar 13® to market and seek to maintain the highest quality standards.
To explain the manufacturing process of Prevenar 13®, we start with the production of the polysaccharides. These are repeated unit of sugars bonded together, present on the surface of the bacterial capsule.
There are 3 main processes: Fermentation, clarification and purification.
First, during the fermentation process, 13 different types of the bacteria S. pneumoniae are grown in production fermenters.
Each of these is a specific strain of the bacteria that expresses a unique polycapsular polysaccharide which has been assigned an individual identification number, referred to as a serotype.
Through clarification and then purification stages, the 13 different polysaccharides essential for Prevenar 13® are produced.
Quality and safety are built into every step of the polysaccharide manufacturing process and includes a variety of tests and checks throughout the process to help ensure consistency in every batch.
The 13 polysaccharides are then stored and are ready for the next stage.
Meanwhile, the carrier protein called CRM197 is manufactured. Bacterial cells in vials are grown under controlled conditions in increasing volumes of growth media until the final fermentation step, when the protein is produced by the bacteria. It is then processed through ultra-filtration and column chromatography.
Finally the CRM197 is bottled and stored in a frozen state. Automation is utilised throughout the process to ensure each batch is processed the same, assuring high quality standards.
CRM197, cross-reactive-material 197; PCV, pneumococcal conjugate vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.